Eli Lilly and Co says its experimental Alzheimer's drug appeared to slow worsening of the mind-robbing disease in a large study.In the 18-month trial, people in the early stages of Alzheimer's who received infusions of donanemab showed 35 per cent less decline in thinking skills compared to those given a dummy drug, Lilly announced in a press release.The drug is designed to target and clear away a sticky protein called beta-amyloid that builds up into brain-clogging plaques that are one hallmark of Alzheimer's.
Load More
Load More